PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$37.91 USD
+0.48 (1.28%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $37.95 +0.04 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 101 - 120 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Program Gathering Steam, Price Target to $43
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Ataluren Launch Pushout and Limited Near-Term Catalyst Hurting Stock
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
European Commission Says Yeah to Translarna
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Competitor Progress Highlights Unmet Clinical Need
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
We initiate with a Buy rating and $34 target price
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
We initiate with a Buy rating and $34 target price
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Q1:14 Update - New Ataluren Indications Coming, Roche SMA Partnership to Yield Derisking by YE:14
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MDA Conference Preview: DMD and SMA Updates - RNA''s DEMAND V Data Monday
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Q4:13 Update: Buyers on Weakness PTCT Remains Undervalued 2014 Catalysts Ahead - New Indications for Ataluren Underappreciated - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Data Update: ISIS SMA Candidate to Inform and Potentially Expedite Development of PTC/ROCHE''s Oral RG7800 for SMA - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Data Update: ISIS SMA Candidate to Inform and Potentially Expedite Development of PTC/ROCHE''s Oral RG7800 for SMA - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Data Update: ISIS SMA Candidate to Inform and Potentially Expedite Development of PTC/ROCHE''s Oral RG7800 for SMA - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Roche Call Highlights PTC SMA Candidate Collaboration - RG7800 in the Clinic, Potential Mechanistic Validation in Healthy Volunteers
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C